Cancer drug safety tracked in ongoing rollover trial
NCT ID NCT06788509
First seen Jun 26, 2026 · Last updated Jul 31, 2026 · Updated 4 times
Summary
This study monitors long-term safety in 120 cancer patients who are already benefiting from treatments like JNJ-75348780, safimaltib, or ibrutinib in earlier trials. Participants have blood cancers, solid tumors, or prostate cancer. The goal is to track serious side effects over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- JNJ-75348780, safimaltib, and ibrutinib
- What this could lead to
- If successful, this study will confirm the long-term safety of these cancer drugs, supporting their continued use in patients who benefit.
- What could go wrong
- This is an early-phase rollover study focused on safety, not efficacy. It enrolls only patients already benefiting, so results may not apply to all. Side effects remain possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Aidport Sp z o o
Skorzewo, 60-185, Poland
-
Alexandra Hospital
Athens, 115 28, Greece
-
Arensia Exploratory Medicine
Tbilisi, Postal code 0112, Georgia
-
Arensia Exploratory Medicine
Chisinau, 2025, Moldova
-
CHU Nantes
Nantes, 44093, France
-
Carmel Medical Center
Haifa, 3436212, Israel
-
Chang Kung Memorial Hospital
Kaohsiung City, 833, Taiwan
-
China Medical University Hospital
Taichung, 404327, Taiwan
-
Clinica Univ. de Navarra
Pamplona, 31008, Spain
-
Ghent University Hospital
Ghent, 9000, Belgium
-
Hadassah University Hospita Ein Kerem
Jerusalem, 9112001, Israel
-
Hopital Claude Huriez
Lille, 59000, France
-
Hosp Clinico Univ de Salamanca
Salamanca, 37007, Spain
-
Hosp Univ Fund Jimenez Diaz
Madrid, 28040, Spain
-
Hosp Univ Vall D Hebron
Barcelona, 08035, Spain
-
Hosp Univ Vall D Hebron 1
Barcelona, 08035, Spain
-
Hosp. Clinic de Barcelona
Barcelona, 08036, Spain
-
Hosp. Univ. 12 de Octubre
Madrid, 28041, Spain
-
Institut Gustave Roussy
Villejuif, 94805, France
-
Linear Clinical Research Ltd
Nedlands, 6009, Australia
-
Macquarie University Hospital
Macquarie University, 2109, Australia
-
Medical Center of Limited Liability Company Arensia Exploratory Medicine
Kyiv, 01135, Ukraine
-
National Cheng Kung University Hospital
Tainan, 704, Taiwan
-
National Hospital Organization Nagoya Medical Center
Nagoya, 460-0001, Japan
-
National Taiwan University Hospital
Taipei, 100, Taiwan
-
Pratia MCM Krakow
Krakow, 30-727, Poland
-
Rambam Med.Center - Hematology Institute
Haifa, 3109601, Israel
-
Rambam Medical Center
Haifa, 3109601, Israel
-
Scientia Clinical Research
Randwick, 2031, Australia
-
Severance Hospital Yonsei University Health System
Seoul, 03722, South Korea
-
St Bartholomews Hospital
London, EC1A 7BE, United Kingdom
-
Tel Aviv Sourasky Medical Center
Tel Aviv, 64239, Israel
-
The Cancer Institute Hospital of JFCR
Tokyo, 135 8550, Japan
-
University Hospitals Of Leicester Nhs Trust
Leicester, Le1 5ww, United Kingdom
-
University Hospitals Plymouth NHS Trust
Plymouth, PL6 8DH, United Kingdom
-
Uniwersyteckie Centrum Kliniczne Osrodek Badan Klinicznych Wczesnych Faz
Gdansk, 80 214, Poland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Chemo combo vs. radioactive drug: which tames aggressive prostate cancer?
- Could muscle loss predict blood cancer outcomes?
- Can a new pill outsmart resistant prostate cancer?
- A simple screening program could transform cancer aftercare
- Can a radioactive 'Smart Bomb' outsmart advanced prostate cancer?
- A new program aims to ease the 'Lost in Transition' struggle for cancer survivors